DBV Technologies announces NEJM publication of Phase 3 EPITOPE trial for Viaskin Peanut in toddlers

DBV Technologies S.A.

NEJM published Phase 3 EPITOPE data showing Viaskin Peanut statistically superior to placebo in desensitizing toddlers (1-3 years) to peanut.
Treatment responder rates: 67.0% for Viaskin Peanut vs 33.5% for placebo after 12 months.
No FDA-approved treatment options exist for peanut-allergic children under 4 years; DBV is advancing regulatory efforts for this age group.
Viaskin Peanut was well-tolerated with low rates of treatment-related anaphylaxis and epinephrine use; local application site reactions decreased over time.
Editorial in NEJM called the data 'very good news' for toddlers with peanut allergy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.